Service of Nephrology, Valais Hospital, Avenue du Grand-Champsec 86, 1950, Sion, Switzerland.
Organ Transplant Center, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
BMC Nephrol. 2021 Jul 6;22(1):252. doi: 10.1186/s12882-021-02456-1.
Thrombotic microangiopathy (TMA)-mediated acute kidney injury (AKI) following massive haemorrhage is a rare but severe complication of the post-partum period. It is associated with a poor renal prognosis and a high risk of end-stage kidney disease. Complement activation may occur in this picture. However, whether complement activation, and thus complement blockade, may be critically relevant in this setting is unknown.
A 50 year-old woman presented with massive delayed post-partum haemorrhage (PPH). Despite bleeding control and normalization of coagulation parameters, she rapidly developed AKI stage 3 associated with dysmorphic microhematuria and proteinuria up to 2 g/day with the need of renal replacement therapy. Blood tests showed signs of TMA associated with markedly increased sC5b-9 and factor Bb plasma levels, respectively markers of terminal and alternative complement pathway over-activation. This clinical picture prompted us to initiate anti-C5 therapy. sC5b-9 normalized within 12 h after the first dose of eculizumab, factor Bb and C3 after seven days, platelet count after nine days and haptoglobin after 3 weeks. The clinical picture improved rapidly with blood pressure control within 48 h. Diuresis resumed after three days, kidney function rapidly improved and haemodialysis could be discontinued after the sixth and last dose. Serum creatinine returned to normal two years after presentation.
We suggest that massive PPH induced major activation of complement pathways, which ultimately lead to TMA-induced AKI. Various causes, such as oocyte-donation, the potential retention of placental material and the use of tranexamic acid may have contributed to complement activation due to PPH. The prompt administration of anti-C5 therapy may have rapidly restored kidney microcirculation patency, thus reversing signs of TMA and AKI. We propose that complement activation may represent a major pathophysiological player of this complication and may provide a novel therapeutic avenue to improve renal prognosis in TMA-induced AKI following massive PPH.
大量产后出血后发生的血栓性微血管病(TMA)介导的急性肾损伤(AKI)是产后期间罕见但严重的并发症。它与不良的肾脏预后和终末期肾病的高风险相关。在这种情况下可能会发生补体激活。然而,补体激活,以及因此补体阻断,是否在这种情况下至关重要尚不清楚。
一名 50 岁女性因大量产后延迟性出血(PPH)就诊。尽管出血得到控制且凝血参数正常化,但她迅速发展为 AKI 第 3 期,伴有变形性镜下血尿和蛋白尿,高达 2g/天,需要肾脏替代治疗。血液检查显示 TMA 相关的迹象,分别与终末补体途径和替代补体途径过度激活相关的 sC5b-9 和因子 Bb 血浆水平显著增加。这种临床表现促使我们开始进行抗 C5 治疗。在使用依库珠单抗的第一次剂量后 12 小时内 sC5b-9 正常化,第 7 天因子 Bb 和 C3 正常化,第 9 天血小板计数正常化,第 3 周后触珠蛋白正常化。临床情况迅速改善,48 小时内血压得到控制。三天后开始利尿,肾功能迅速改善,第六次(也是最后一次)剂量后可停用血液透析。血清肌酐在发病后两年恢复正常。
我们认为,大量 PPH 诱导了补体途径的主要激活,最终导致 TMA 引起的 AKI。各种原因,如卵母细胞捐赠、胎盘物质的潜在滞留以及使用氨甲环酸,可能由于 PPH 导致了补体激活。及时给予抗 C5 治疗可能迅速恢复肾脏微循环通畅性,从而逆转 TMA 和 AKI 的迹象。我们提出,补体激活可能是这种并发症的主要病理生理因素之一,并可能为改善 TMA 诱导的大量 PPH 后 AKI 的肾脏预后提供新的治疗途径。